

Inventiva to Present the Latest Findings in its RORy program at the 256th National Meeting of the American Chemical Society

Discovery of a new series of quinoline sulfonamides as potent orally inverse RORy inhibitors

Daix (France), August 1st, 2018 – Inventiva S.A. (“Inventiva” or the “Company”), a biopharmaceutical company developing innovative therapies in nonalcoholic steatohepatitis (NASH), Systemic Sclerosis (SSc) and mucopolysaccharidosis (MPS), today announced that Dominique Potin, Inventiva’s Principal Scientist of Medicinal Chemistry, will give a presentation on the Company’s RORy program, entitled “*Discovery of novel quinoline sulfonamide derivatives as potent, selective and orally active RORy inverse agonists*”, at the 256th National Meeting of the American Chemical Society being held on August 19-23, 2018 at the Boston Convention & Exhibition Center (BCEC) in Boston, Massachusetts.

Dr. Potin will present results from a high throughput screening of Inventiva’s library of 248,000 compounds using a GAL4 transactivation assay, which has led to the discovery of a new series of quinoline sulfonamides as potent orally inverse RORy inhibitors. Dr. Potin will discuss the synthesis, structure activity relationship (SAR) and biological activity of these derivatives.

Inventiva and AbbVie, a global, research and development-based biopharmaceutical company, have entered into an agreement to discover and develop available RORy inverse agonists which has led to the development of several orally available inverse RORy inhibitors, showing activity in vivo both in a target engagement model and disease models. The most advanced compound, ABBV-157, has demonstrated a good safety profile during GLP-tox studies and has been selected to enter into Phase I clinical studies. Under the terms of the agreement, Inventiva is eligible for development and sales milestones as well as royalties on sales.

Dr. Potin commented: “*Targeting the IL-17 pathway has become a very attractive approach for the treatment of immuno-inflammatory diseases in recent years. IL-17 antibodies such as secukinumab have validated the interest of blocking IL-17 secretion for such therapy. The nuclear receptor RORy γ is a critical element in the regulation of IL-17. It does indeed play a key role in the differentiation and development of Th17 cells that secrete IL-17A and other pro-inflammatory cytokines, like IL-17F and IL-22. Small molecule RORy γ inhibitors could be useful for the treatment of various diseases such as psoriasis or inflammatory bowel disease.*”

The details of the presentation are as follows:

Presentation Title: “Discovery of novel quinoline sulfonamide derivatives as potent, selective and orally active RORy inverse agonists”
Speaker: Dr. Dominique Potin, Principal Scientist of Medicinal Chemistry, Inventiva
Session Title: General Oral Session
Date: August 19, 2018
Time: 09:30 am (Eastern Time)
Location: MEDI 10, room 210A, Boston Convention & Exhibition Center (BCEC)

About Inventiva: www.inventivapharma.com

Inventiva is a biopharmaceutical company specialized in the development of drugs interacting with nuclear receptors, transcription factors and epigenetic modulators. Inventiva's research engine opens up novel breakthrough therapies against fibrotic diseases, cancers and orphan diseases with substantial unmet medical needs.

Lanifibranor, its lead product, is an anti-fibrotic treatment acting on the three alpha, gamma and delta PPARs (peroxisome proliferator-activated receptors), which play key roles in controlling the fibrotic process. Its anti-fibrotic action targets two initial indications with substantial unmet medical need: NASH, a severe and increasingly prevalent liver disease already affecting over 30 million people in the United States, and SSC, a disease with a very high mortality rate and for which there is no approved treatment to date.

Inventiva is also developing a second clinical program with odiparcil (IVA 336) for the treatment of patients with mucopolysaccharidosis type VI (or Maroteaux-Lamy syndrome), a rare and severe gene disease affecting children. Odiparcil has also the potential to address other MPS types, characterized by the accumulation of chondroitin or dermatan sulfate (MPS I or Hurler/Sheie syndrome, MPS II or Hunter syndrome, MPS IVa or Morquio syndrome and MPS VII or Sly syndrome). Inventiva is also developing a portfolio of early research projects in the field of oncology.

Inventiva benefits from partnerships with world-leading research entities such as the Institut Curie in the field of oncology. Two strategic partnerships have also been established with world-class major pharmaceutical companies AbbVie and Boehringer Ingelheim in the fields of autoimmune diseases (specifically in psoriasis) and fibrosis respectively. These partnerships provide milestone payments to Inventiva upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on the products resulting from the partnerships.

Inventiva employs over 100 highly qualified employees and owns state-of-the-art R&D facilities near Dijon, acquired from the international pharmaceutical group Abbott. The Company owns, a proprietary chemical library of over 240,000 molecules as well as integrated biology, chemistry, ADME and pharmacology platforms.

Contacts

Inventiva

Frédéric Cren
Chief Executive Officer
info@inventivapharma.com
+33 3 80 44 75 00

Brunswick

Julien Trosdorf / Yannick Tetzlaff
Media relations
inventiva@brunswickgroup.com
+33 1 53 96 83 83

LifeSci Advisors

Chris Maggos
Investor relations
chris@lifesciadvisors.com
+41 79 367 6254

Important Notice

This press release contains forward-looking statements, forecasts and estimates with respect to the clinical development plans, business and regulatory strategy, and anticipated future performance of Inventiva and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will" and "continue" and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva's control. There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and

estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements.

Please refer to the "Document de référence" filed with the Autorité des Marchés Financiers on April 13, 2018 under n° R.18-013 for additional information in relation to such factors, risks and uncertainties.

Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements.